Targepeutics to Present Latest DMG and GBM Data at Society for NeuroOncology Annual Meeting

Targepeutics is presenting the latest efficacy data related to treatment of GBM and DMG tumors with the novel immunotoxin, GB13. This data is presented as a poster presentation during the 28th Annual Meeting for the Society of NeuroOncology, being held in Vancouver, BC from November 15-19.

Dr Randy Schrecengost, Chief Scientific Officer, will present the poster entitled “GB13 is a potent treatment for IL13Rα2-expressing GBM and DMG and improves standard-of-care therapy” during the Friday evening poster session. Key highlights from the data demonstrate that convection enhanced delivery (CED) is a viable drug delivery mechanism for GB13 to significantly reduce tumor volume and increase survival. Excitingly, GB13 pretreatment substantially increases radiation-induced cell death and dramatically improved survival outcomes, compared to single agent conditions.

Details for the presentation:

Title: GB13 is a potent treatment for IL13Rα2-expressing GBM and DMG and improves standard-of-care therapy

Presenter: Randy Schrecengost, PhD, Targepeutics CSO

Abstract number: EXTH-54